ReviewJournal of hepatocellular carcinoma2022
Macrotrabecular-Massive Hepatocellular Carcinoma: Light and Shadow in Current Knowledge.
Review in Journal of hepatocellular carcinoma, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Artificial intelligence in hepatocellular carcinoma: imaging-based subtyping and prediction of treatment response and prognosis.Abdominal radiology (New York) · 2026Review
- Interpretable prediction of macrotrabecular-massive HCC and recurrence-free survival by integrating MRI LI-RADS features with deep learning habitat radiomics.European radiology experimental · 2026Observational
- CRAFITY and PALBI Define a Machine Learning-Supported Prognostic Framework in Hepatocellular Carcinoma-Data from an Eastern European Cohort with Low Macrotrabecular-Massive Prevalence.Diseases (Basel, Switzerland) · 2026Article
- [Detection and differentiation of atypical hepatocellular carcinomas].Radiologie (Heidelberg, Germany) · 2026Article
- CT-Based Nested Habitats Analysis for Early Recurrence Prediction and Risk Stratification in Hepatocellular Carcinoma: Development and Multicenter Validation Across Four Cohorts.Annals of surgical oncology · 2026Article
- A Non-Invasive Integrated Model for Accurate Preoperative Identification of the Aggressive Macrotrabecular-Massive Subtype of Hepatocellular Carcinoma: A Single-Center Retrospective Study.Diagnostics (Basel, Switzerland) · 2026Article
- Central histopathological review of a European hepatocellular carcinoma cohort: impact of the WHO 2019 classification on histological diagnosis and TNM staging.Virchows Archiv : an international journal of pathology · 2026Article
- Macrotrabecular-massive subtype in hepatocellular carcinoma based on contrast-enhanced CT: deep learning outperforms machine learning.Insights into imaging · 2025Article
- [Study of a nomogram model of gadoxetate disodium-enhanced magnetic resonance imaging for the preoperative diagnosis of proliferative hepatocellular carcinoma and its value].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Preoperative Prediction of Macrotrabecular-Massive Hepatocellular Carcinoma Using Machine Learning-Based Ultrasomics.Journal of hepatocellular carcinoma · 2025Article
- Article
- Preoperative prediction of macrotrabecular-massive hepatocellular carcinoma through dynamic contrast-enhanced magnetic resonance imaging-based radiomics.World journal of gastroenterology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The subject of this narrative review is macrotrabecular-massive hepatocellular carcinoma (MTM-HCC). Despite their rarity, these tumours are of general interest because of their epidemiological and clinical features and for representing a distinct model of the interaction between the angiogenetic system and neoplastic cells. The MTM-HCC subtype is associated with various adverse biological and pathological parameters (the Alfa-foetoprotein (AFP) serum level, tumour size, vascular invasion, and satellite nodules) and is a key determinant of patient prognosis, with a strong and independent predictive value for early and overall tumour recurrence. Gene expression profiling has demonstrated that angiogenesis activation is a hallmark feature of MTM-HCC, with overexpression of both angiopoietin 2 (ANGPT2) and vascular endothelial growth factor A (VEGFA).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.